Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Non Operating Income: 2015-2024

Historic Non Operating Income for Adma Biologics (ADMA) over the last 9 years, with Dec 2024 value amounting to -$13.3 million.

  • Adma Biologics' Non Operating Income fell 21.05% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.2 million, marking a year-over-year increase of 72.94%. This contributed to the annual value of -$13.3 million for FY2024, which is 73.39% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Non Operating Income is -$13.3 million, which was up 73.39% from -$49.9 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Non Operating Income registered a high of -$11.8 million during FY2020, and its lowest value of -$49.9 million during FY2023.
  • Moreover, its 3-year median value for Non Operating Income was -$26.5 million (2022), whereas its average is -$29.9 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 99.93% in 2022, then soared by 73.39% in 2024.
  • Adma Biologics' Non Operating Income (Yearly) stood at -$11.8 million in 2020, then dropped by 12.25% to -$13.3 million in 2021, then crashed by 99.93% to -$26.5 million in 2022, then crashed by 87.92% to -$49.9 million in 2023, then skyrocketed by 73.39% to -$13.3 million in 2024.